clonidine has been researched along with Syndrome in 43 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Syndrome: A characteristic symptom complex.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Now, we sought to determine if we could detect a GH response to hypoglycemia (ITT: insulin tolerance test) or clonidine (CL) in these patients." | 9.12 | GH response to hypoglycemia and clonidine in the GH-releasing hormone resistance syndrome. ( Aguiar-Oliveira, MH; Almeida, JC; Britto, AV; Farias, CT; Oliveira, CR; Oliveira, JL; Parmigiani, G; Prado, CM; Salvatori, R; Serpa, MG; Vicente, TA, 2006) |
| "We report a rare case of Shapiro's syndrome variantrevealed by episodes of headache with spontaneous hypothermia witheffectiveness of clonidine therapy in a 76-year-old Parkinson's disease woman." | 8.02 | Episodic headache with spontaneous hypothermia reveal Shapiro's syndrome variant with effectiveness of clonidine therapy. ( Andriuta, D; Aubignat, M; Krystkowiak, P; Tir, M, 2021) |
| " The mother took clonidine during pregnancy." | 7.66 | Roberts's syndrome and clonidine. ( Beshara, D; Levy, JM; Stoll, C, 1979) |
| "Clonidine was safe to administer and should be considered early when treating IS." | 5.72 | Use of clonidine in the treatment of Irukandji syndrome: A 4-year retrospective cohort study on safety, efficacy and clinical utility. ( Isman, A; Little, M; Seymour, J, 2022) |
| "Clonidine therapy was also associated with a return to normal central temperature regulation." | 5.28 | Clonidine therapy for Shapiro's syndrome. ( Anderson, JA; Edwards, CR; Walker, BR, 1992) |
| " Now, we sought to determine if we could detect a GH response to hypoglycemia (ITT: insulin tolerance test) or clonidine (CL) in these patients." | 5.12 | GH response to hypoglycemia and clonidine in the GH-releasing hormone resistance syndrome. ( Aguiar-Oliveira, MH; Almeida, JC; Britto, AV; Farias, CT; Oliveira, CR; Oliveira, JL; Parmigiani, G; Prado, CM; Salvatori, R; Serpa, MG; Vicente, TA, 2006) |
| "Six subjects with the phobic-anxiety syndrome were treated in a controlled, crossover trial of clonidine hydrochloride v imipramine hydrochloride for periods of four weeks each." | 5.05 | Panic-induced elevation of plasma MHPG levels in phobic-anxious patients. Effects of clonidine and imipramine. ( Elsworth, JD; Ko, GN; Leigh, H; Redmond, DE; Rifkin, BG; Roth, RH, 1983) |
| "The paper considers mechanisms of action and clinical efficacy of the drug sirdalud (tizanidine) in painful musculotonic syndromes." | 4.79 | [The use of sirdalud in painful muscle tonic syndromes]. ( Damulin, IV, 1997) |
| "We report a rare case of Shapiro's syndrome variantrevealed by episodes of headache with spontaneous hypothermia witheffectiveness of clonidine therapy in a 76-year-old Parkinson's disease woman." | 4.02 | Episodic headache with spontaneous hypothermia reveal Shapiro's syndrome variant with effectiveness of clonidine therapy. ( Andriuta, D; Aubignat, M; Krystkowiak, P; Tir, M, 2021) |
| " All the patients had excessive pressor and tachycardia responses to the mental-arithmetic and cold pressor tests and marked hypersensitivity to clonidine." | 3.68 | The diagnosis and treatment of baroreflex failure. ( Biaggioni, I; Hollister, AS; Mosqueda-Garcia, R; Netterville, JL; Robertson, D; Robertson, RM, 1993) |
| "15 mg clonidine (Catapresan) in 11 patients (averaged age 60 years) with symptomatic bradycardia (dizzy spells, syncope, palpitations)." | 3.66 | [Clinidine-induced bradycardia: studies of the effect on the human sinus node (author's transl)]. ( Horn, H; Neuss, H; Schlepper, M; Thormann, J, 1981) |
| " The mother took clonidine during pregnancy." | 3.66 | Roberts's syndrome and clonidine. ( Beshara, D; Levy, JM; Stoll, C, 1979) |
| " Advantages, potential side effects, and dosing for multiple modes of delivery are discussed." | 2.43 | Long-term use of clonidine in a critically-ill infant. ( Lowery, R; Polaner, DM; Zuk, J, 2005) |
| "Pheochromocytomas are catecholamine-producing tumors, representing one of the most important causes of secondary hypertension." | 2.40 | [Clinical and endocrine diagnosis of pheochromocytoma]. ( Kopf, D; Lehnert, H; Mundschenk, J; Schulz, C, 1997) |
| "Clonidine was safe to administer and should be considered early when treating IS." | 1.72 | Use of clonidine in the treatment of Irukandji syndrome: A 4-year retrospective cohort study on safety, efficacy and clinical utility. ( Isman, A; Little, M; Seymour, J, 2022) |
| "The numb chin syndrome is a rare manifestation of intractable pain in the palliative care setting and represents a major therapeutic challenge." | 1.43 | Spontaneous Osteonecrosis of the Jaw During Bisphosphonate Therapy: An Unusual Etiology of the Numb Chin Syndrome. ( Bardelli, D; Fusi-Schmidhauser, T, 2016) |
| " There were no significant changes in the half-life (8." | 1.29 | Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. ( Cohen, P; Diamond, FB; Fielder, PJ; Gargosky, S; Guevara-Aguirre, J; Rosenbloom, AL; Rosenfeld, RG; Vaccarello, MA; Wilson, K, 1993) |
| "Clonidine therapy was also associated with a return to normal central temperature regulation." | 1.28 | Clonidine therapy for Shapiro's syndrome. ( Anderson, JA; Edwards, CR; Walker, BR, 1992) |
| "Clonidine therapy was associated with an initial dramatic decrease in the frequency of diaphoretic episodes as well as with a fall in NE release rate and increases in NE clearance and volume of distribution." | 1.28 | Altered norepinephrine metabolism in Shapiro's syndrome. ( Cahalan, DD; Forrester, JM; Halter, JB; Linares, OA; Rosen, SG; Sanfield, JA, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (37.21) | 18.7374 |
| 1990's | 14 (32.56) | 18.2507 |
| 2000's | 7 (16.28) | 29.6817 |
| 2010's | 4 (9.30) | 24.3611 |
| 2020's | 2 (4.65) | 2.80 |
| Authors | Studies |
|---|---|
| Isman, A | 1 |
| Seymour, J | 1 |
| Little, M | 2 |
| Aubignat, M | 1 |
| Tir, M | 1 |
| Krystkowiak, P | 1 |
| Andriuta, D | 1 |
| Duma, SN | 1 |
| Fusi-Schmidhauser, T | 1 |
| Bardelli, D | 1 |
| Somerville, A | 1 |
| Sriganesh, K | 1 |
| Smita, V | 1 |
| Aravind, HS | 1 |
| Damulin, IV | 2 |
| Silvani, P | 1 |
| Camporesi, A | 1 |
| Zoia, E | 1 |
| Leoncino, S | 1 |
| Salvo, I | 1 |
| Lowery, R | 1 |
| Zuk, J | 1 |
| Polaner, DM | 1 |
| Tobias, JD | 1 |
| Vranken, JH | 1 |
| van Kan, HJ | 1 |
| van der Vegt, MH | 1 |
| Salvatori, R | 1 |
| Serpa, MG | 1 |
| Parmigiani, G | 1 |
| Britto, AV | 1 |
| Oliveira, JL | 1 |
| Oliveira, CR | 1 |
| Prado, CM | 1 |
| Farias, CT | 1 |
| Almeida, JC | 1 |
| Vicente, TA | 1 |
| Aguiar-Oliveira, MH | 1 |
| Hubbell, FA | 1 |
| Weber, MA | 1 |
| Houston, MC | 1 |
| Piccione, E | 1 |
| Sesti, F | 1 |
| Manna, C | 1 |
| Meinck, HM | 2 |
| Ricker, K | 1 |
| Conrad, B | 2 |
| Ko, GN | 1 |
| Elsworth, JD | 1 |
| Roth, RH | 1 |
| Rifkin, BG | 1 |
| Leigh, H | 1 |
| Redmond, DE | 1 |
| Thormann, J | 1 |
| Neuss, H | 1 |
| Horn, H | 1 |
| Schlepper, M | 1 |
| Vaccarello, MA | 1 |
| Diamond, FB | 1 |
| Guevara-Aguirre, J | 1 |
| Rosenbloom, AL | 1 |
| Fielder, PJ | 1 |
| Gargosky, S | 1 |
| Cohen, P | 1 |
| Wilson, K | 1 |
| Rosenfeld, RG | 1 |
| Hong, C | 1 |
| Song, KY | 1 |
| Wong, V | 1 |
| Sobala, G | 1 |
| Losowsky, M | 1 |
| Wulf, H | 1 |
| Gleim, M | 1 |
| Mignat, C | 1 |
| Reynisdottir, S | 1 |
| Ellerfeldt, K | 1 |
| Wahrenberg, H | 1 |
| Lithell, H | 1 |
| Arner, P | 1 |
| Robertson, D | 1 |
| Hollister, AS | 1 |
| Biaggioni, I | 1 |
| Netterville, JL | 1 |
| Mosqueda-Garcia, R | 1 |
| Robertson, RM | 1 |
| McCracken, JT | 1 |
| Martin, W | 1 |
| Vorobeĭchik, IaM | 1 |
| Kukushkin, ML | 1 |
| Reshetniak, VK | 1 |
| Ovechkin, AM | 1 |
| Gnezdilov, AV | 1 |
| Lehnert, H | 1 |
| Schulz, C | 1 |
| Mundschenk, J | 1 |
| Kopf, D | 1 |
| Burnstein, Y | 1 |
| Shelton, K | 1 |
| Higginbotham, EJ | 1 |
| Mercadante, S | 1 |
| Serretta, R | 1 |
| Sapio, M | 1 |
| Villari, P | 1 |
| Calderone, L | 1 |
| Ejaz, AA | 1 |
| Meschia, JF | 1 |
| Gordon, VM | 1 |
| Opfer-Gehrking, TL | 1 |
| Novak, V | 1 |
| Low, PA | 1 |
| Yudkin, JS | 1 |
| Bruce, DL | 1 |
| Croley, TF | 1 |
| Lee, JS | 1 |
| Stoll, C | 1 |
| Levy, JM | 1 |
| Beshara, D | 1 |
| Walker, BR | 1 |
| Anderson, JA | 1 |
| Edwards, CR | 1 |
| Galassi, AR | 1 |
| Kaski, JC | 1 |
| Pupita, G | 1 |
| Vejar, M | 1 |
| Crea, F | 1 |
| Maseri, A | 1 |
| Sato, T | 1 |
| Igarashi, N | 1 |
| Minami, S | 1 |
| Okabe, T | 1 |
| Hashimoto, H | 1 |
| Hasui, M | 1 |
| Kato, E | 1 |
| Pranzatelli, MR | 1 |
| Schultz, L | 1 |
| Snodgrass, SR | 1 |
| Sanfield, JA | 1 |
| Linares, OA | 1 |
| Cahalan, DD | 1 |
| Forrester, JM | 1 |
| Halter, JB | 1 |
| Rosen, SG | 1 |
| Lechin, F | 1 |
| van der Dijs, B | 1 |
| Jakubowicz, D | 1 |
| Camero, RE | 1 |
| Villa, S | 1 |
| Arocha, L | 1 |
| Lechin, AE | 1 |
| Schneider, KW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist[NCT03070730] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 2011-08-15 | Terminated (stopped due to Recruitment was slow and subjects declined participation after signing the ICF.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: up to 3 days after randomization
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: Up to 3 days after randomization
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
7 reviews available for clonidine and Syndrome
| Article | Year |
|---|---|
[Spastic syndrome and main directions of its treatment].
Topics: Anti-Dyskinesia Agents; Botulinum Toxins; Clonidine; Exercise Therapy; Humans; Motor Neuron Disease; | 2003 |
Long-term use of clonidine in a critically-ill infant.
Topics: Analgesics; Clonidine; Critical Illness; Fatal Outcome; Follow-Up Studies; Hemangioma; Humans; Infan | 2005 |
Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome.
Topics: Acute Disease; Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Bethanidine; Blood Pressure; Cloni | 1981 |
[Possibilities and limits of non-hormonal therapy of the menopausal syndrome].
Topics: Bromocriptine; Climacteric; Clonidine; Dopamine; Female; Gonadotropin-Releasing Hormone; Humans; Men | 1984 |
[Clinical and endocrine diagnosis of pheochromocytoma].
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Catecholamines; Clonidine; Humans; Iodine Radioisoto | 1997 |
[The use of sirdalud in painful muscle tonic syndromes].
Topics: Clonidine; Humans; Muscle Relaxants, Central; Muscle Spasticity; Muscle Tonus; Muscular Diseases; Pa | 1997 |
Thalamic hemorrhage following carotid endarterectomy-induced labile blood pressure: controlling the liability with clonidine--a case report.
Topics: Aged; Antihypertensive Agents; Baroreflex; Blood Pressure Monitoring, Ambulatory; Cerebral Hemorrhag | 1999 |
4 trials available for clonidine and Syndrome
| Article | Year |
|---|---|
[A role of treatment of autonomic syndrome in patients with tension-type headache].
Topics: Administration, Oral; Adult; Analgesics, Non-Narcotic; Autonomic Nervous System; Autonomic Nervous S | 2015 |
GH response to hypoglycemia and clonidine in the GH-releasing hormone resistance syndrome.
Topics: Adolescent; Adult; Blood Glucose; Body Height; Child; Child, Preschool; Clonidine; Dwarfism, Pituita | 2006 |
Panic-induced elevation of plasma MHPG levels in phobic-anxious patients. Effects of clonidine and imipramine.
Topics: Adult; Anxiety Disorders; Clonidine; Double-Blind Method; Fear; Female; Glycols; Humans; Imipramine; | 1983 |
[The treatment of the phantom pain syndrome with tizanidine].
Topics: Adult; Aged; Analgesics; Chronic Disease; Clonidine; Double-Blind Method; Female; Humans; Male; Midd | 1997 |
32 other studies available for clonidine and Syndrome
| Article | Year |
|---|---|
Use of clonidine in the treatment of Irukandji syndrome: A 4-year retrospective cohort study on safety, efficacy and clinical utility.
Topics: Analgesics; Analgesics, Opioid; Bites and Stings; Clonidine; Cnidarian Venoms; Humans; Retrospective | 2022 |
Episodic headache with spontaneous hypothermia reveal Shapiro's syndrome variant with effectiveness of clonidine therapy.
Topics: Aged; Agenesis of Corpus Callosum; Clonidine; Female; Headache; Humans; Hyperhidrosis; Hypothermia; | 2021 |
Spontaneous Osteonecrosis of the Jaw During Bisphosphonate Therapy: An Unusual Etiology of the Numb Chin Syndrome.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bupivaca | 2016 |
Clonidine to treat Irukandji syndrome.
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics; Bites and Stings; Clonidine; Cnidarian Venoms; Fem | 2016 |
Clonidine as a sole sedative agent for MRI study in a child with Joubert syndrome.
Topics: Adrenergic alpha-Agonists; Cerebellar Diseases; Child, Preschool; Clonidine; Conscious Sedation; Hum | 2010 |
Anesthetic management in a child with Coffin-Siris syndrome.
Topics: Abnormalities, Multiple; Amides; Analgesia, Epidural; Analgesics; Anesthetics, Inhalation; Anestheti | 2004 |
Dexmedetomidine in the treatment of cyclic vomiting syndrome.
Topics: Adrenergic alpha-Agonists; Bradycardia; Child; Clonidine; Dexmedetomidine; Humans; Hypnotics and Sed | 2005 |
Stability and compatibility of a meperidine-clonidine mixture in portable pump reservoirs for the management of cancer pain syndromes.
Topics: Analgesics; Analgesics, Opioid; Clonidine; Complex Mixtures; Drug Combinations; Drug Stability; Huma | 2006 |
Adverse effects of sudden withdrawal of antihypertensive medication.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Clonidine; Drug Therapy, Combi | 1980 |
The stiff-man syndrome: new pathophysiological aspects from abnormal exteroceptive reflexes and the response to clomipramine, clonidine, and tizanidine.
Topics: Adult; Brain Stem; Clomipramine; Clonidine; Diazepam; Electromyography; Female; Humans; Muscle Rigid | 1984 |
[Clinidine-induced bradycardia: studies of the effect on the human sinus node (author's transl)].
Topics: Aged; Arrhythmias, Cardiac; Bradycardia; Carotid Sinus; Clonidine; Female; Heart Rate; Humans; Male; | 1981 |
Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome.
Topics: Adult; Blood Glucose; Calcium; Carrier Proteins; Clonidine; Ecuador; Female; Growth Hormone; Half-Li | 1993 |
Effect of apraclonidine hydrochloride on the attack of Posner-Schlossman syndrome.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Clonidine; Female; Glaucoma, Open-Angle; Hemodyn | 1993 |
A case of narcotic bowel syndrome successfully treated with clonidine.
Topics: Abdominal Pain; Adult; Analgesics, Opioid; Chronic Disease; Clonidine; Female; Humans; Substance Wit | 1994 |
The stability of mixtures of morphine hydrochloride, bupivacaine hydrochloride, and clonidine hydrochloride in portable pump reservoirs for the management of chronic pain syndromes.
Topics: Bupivacaine; Chronic Disease; Clonidine; Drug Combinations; Drug Stability; Humans; Infusion Pumps; | 1994 |
Multiple lipolysis defects in the insulin resistance (metabolic) syndrome.
Topics: Adipose Tissue; Aged; Clonidine; Dose-Response Relationship, Drug; Humans; Insulin Resistance; Isopr | 1994 |
The diagnosis and treatment of baroreflex failure.
Topics: Adult; Baroreflex; Blood Pressure; Catecholamines; Clonidine; Female; Humans; Hypertension; Male; Mi | 1993 |
Clonidine side effect.
Topics: Adrenergic alpha-Agonists; Aggression; Autistic Disorder; Child; Clonidine; Depression; Humans; Male | 1997 |
Glaucomatocyclitic crisis in a child.
Topics: Adolescent; Clonidine; Corneal Edema; Diagnosis, Differential; Drug Therapy, Combination; Glaucoma; | 1998 |
When all else fails: stepwise multiple solutions for a complex cancer pain syndrome.
Topics: Aged; Analgesics; Analgesics, Opioid; Anesthetics, Local; Bupivacaine; Cholinesterase Inhibitors; Cl | 1999 |
Hemodynamic and symptomatic effects of acute interventions on tilt in patients with postural tachycardia syndrome.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Antihypertensive Agents; Clonidine; Female; Hemodynamics; | 2000 |
Clonidine withdrawal syndrome in Tanzania--a substantial risk.
Topics: Adult; Clonidine; Female; Humans; Hypertension; Long-Term Care; Male; Middle Aged; Substance Withdra | 1978 |
Preoperative clonidine withdrawal syndrome.
Topics: Antihypertensive Agents; Clonidine; Humans; Male; Middle Aged; Preoperative Care; Substance Withdraw | 1979 |
Roberts's syndrome and clonidine.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Cleft Lip; Cleft Palate; Clonidine; Diazepam; | 1979 |
Clonidine therapy for Shapiro's syndrome.
Topics: Adult; Agenesis of Corpus Callosum; Body Temperature Regulation; Clonidine; Humans; Hyperhidrosis; H | 1992 |
Lack of evidence for alpha-adrenergic receptor-mediated mechanisms in the genesis of ischemia in syndrome X.
Topics: Adult; Angina Pectoris; Clonidine; Coronary Angiography; Coronary Disease; Electrocardiography; Exer | 1989 |
Recurrent attacks of vomiting, hypertension and psychotic depression: a syndrome of periodic catecholamine and prostaglandin discharge.
Topics: Adolescent; Adrenocorticotropic Hormone; Arginine Vasopressin; Child, Preschool; Clonidine; Dinopros | 1988 |
High-dose clonidine motor syndrome: relationship to serotonin syndrome.
Topics: Adrenergic alpha-Antagonists; Animals; Behavior, Animal; Brain; Clonidine; Dose-Response Relationshi | 1987 |
Altered norepinephrine metabolism in Shapiro's syndrome.
Topics: Aged; Agenesis of Corpus Callosum; Clonidine; Female; Humans; Hypothermia; Middle Aged; Norepinephri | 1989 |
Neuropharmacological investigations in the stiff-man syndrome.
Topics: Adrenergic Fibers; Central Nervous System Diseases; Clonidine; Diazepam; Female; Humans; Methampheta | 1986 |
Effects of clonidine on blood pressure, noradrenaline, cortisol, growth hormone, and prolactin plasma levels in high and low intestinal tone depressed patients.
Topics: Blood Pressure; Clonidine; Depressive Disorder; Female; Gastrointestinal Motility; Growth Hormone; H | 1985 |
[Etiology and therapy of the parotid gland syndrome].
Topics: Antihypertensive Agents; Chewing Gum; Clonidine; Dihydroxyphenylalanine; Eating; Humans; Neostigmine | 1973 |